Tags : Xcenda


Insights+ Key Biosimilars Events of April 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC’s approval for […]Read More


Xcenda’s FormularyDecisions Launches Resource Hub for Biosimilars

Shots: FormularyDecisions’ new feature will provide registered users with centralized access to pertinent product and drug pipeline information, regulatory guidance and state-specific substitution laws The biosimilar hub will provide users an interactive chart of the US biosimilar market landscape, curated biosimilar resources and dynamic repository of state substitution laws for biosimilar products With the hub, […]Read More